Onkologie. 2023:17(1):62-66 | DOI: 10.36290/xon.2023.014
Cemiplimab in treating locally advanced NSCLC
- Klinika plicních nemocí a tuberkulózy, LF UP a FN Olomouc
A case is reported of a female patient who was diagnosed with an inoperable, stage IIIB adenocarcinoma of the right lung. Given the high PD-L1 positivity of 90% and negativity of activating mutations, immunotherapy was chosen as the treatment modality with a real chance for a therapeutic response. Due to comorbidities, disease extent (carcinomatous lymphangitis, satellite lesion), and the patient's age, chemoradiotherapy (CRT), whether in concurrent (cCRT) or sequential (sCRT) form, was not indicated because of a high risk of serious complications. For these reasons, the patient was started on cemiplimab which is currently the only molecule among immuno-oncology therapeutics to have been approved for the treatment of locally advanced non-small cell lung carcinoma (NSCLC) in monotherapy. The treatment with cemiplimab resulted in partial disease regression, with a favourable effect on the patient's clinical condition.
Keywords: NSCLC, cemiplimab, stage III, immunotherapy.
Accepted: February 22, 2023; Published: March 1, 2023 Show citation
References
- Modrá kniha České onkologické společnosti, 28. aktualizace. Brno: Masarykův onkologický ústav, 2022. Available from: www.linkos.cz.
- Seung SJ, Hurry M, Walton RN, et al. Retrospective cohort study of unresectable stage III non-small-cell lung cancer in Canada. Curr Oncol. 2020;27(4):e354-e360. doi: 10.3747/co.27.6047.
Go to original source... 
Go to PubMed... - Agulnik J, Kasymjanova G, Pepe C, et al. Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec. Curr Oncol. 2020;27(5):e459-e466. doi: 10.3747/co.27.6241. Go to original source... Go to PubMed...
- Shang S, Wang R, Wang F, et al. Treatment Patterns for Patients With Unresected Stage III NSCLC: Analysis of the Surveillance Epidemiology, and End Results (SEER) Database. Front. Oncol. 2002;12:874022. doi: 10.3389/fonc.2022.874022. Go to original source... Go to PubMed...
- Zemanova M, Pirker R, Petruzelka L, et al. Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience. Radiol Oncol. 2020;54(2):209-220. doi: 10.2478/raon-2020-0026. PMID: 32463394; PMCID: PMC7276648. Go to original source... Go to PubMed...
- Provencio M, Carcereny E, Rodríguez-Abreu D, et al. Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). Transl Lung Cancer Res. 2019;8(4):461-475. doi: 10.21037/tlcr.2019.08.05. Go to original source... Go to PubMed...
- Committee for the Assessment of NIH Research on Autoimmune Diseases; Board on Population Health and Public Health Practice; Health and Medicine Division; National Academies of Sciences, Engineering, and Medicine. Enhancing NIH Research on Autoimmune Disease. Washington (DC): National Academies Press (US); May 10, 2022.
- Remon J, Hendriks LEL. Targeted therapies for unresectable stage III non-small cell lung cancer. Mediastinum. 2021;5:22. doi: 10.21037/med-21-8. Go to original source... Go to PubMed...
- Goodman CD, Nijman SFM, Senan S, et al. A Primer on Interstitial Lung Disease and Thoracic Radiation. Journal of Thoracic Oncology 2020;15(6):902-913. Go to original source... Go to PubMed...
- Pass HI, Ball D, Scagliotti GV, et al. IASCLC Thoracic Oncology. Elsevier; 2014.
- Yamada M, Kudoh S, Hirata K, et al. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer. 1998;34(1):71-75. doi:10.1016/s0959-8049(97)00377-8. Go to original source... Go to PubMed...
- Ohe Y, Yamamoto S, Suzuki K, et al. Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer. Eur J Cancer. 2001;37(1):54-63. doi:10.1016/s0959-8049(00)00350-6. Go to original source... Go to PubMed...
- Vogelius IR, Bentzen SM. A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol. 2012 November;51(8):975-983. doi:10.3109/0284186X.2012.718093. Go to original source... Go to PubMed...
- Sezer A, Kilickap S, Gumus M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised controlled trial. Lancet 2021;397:592-604. Go to original source... Go to PubMed...
- Bondarenko I, Sezer A, Kilickap S, et al. Clinical benefit of first-line cemiplimab in patients with locally advanced NSCLC: subgroup analysis from EMPOWER-Lung 1. IASLC World Conference on Lung Cancer. 2021;September 8-14, Abstract FP04.03. Go to original source...
- Gümüş M, Chen CI, Ivanescu C, et al. Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥ 50 %: The EMPOWER-Lung 1 study. Cancer. 2023;129(1):118-129. doi:10.1002/cncr.34477. Go to original source... Go to PubMed...